News

Under the deal, the partnership will use MiNA’s small activating RNA (saRNA) therapeutics platform to develop novel compounds for the treatment of fibrotic liver diseases such as NASH.

The operation positions Cerenis at the forefront of the chemotherapy drug delivery and immuno-oncology space. This represents a significant step towards the Company’s strategic objective of developing the

Wellington Management Company LLP, Venrock Healthcare Capital Partners and Cormorant Asset Management joined existing investors OrbiMed, Longitude Capital, Sibling Capital Ventures, Limulus Venture Partners and Vivo Capital in the round. Proceeds will be used to complete the ongoing pivotal TRCA-301 Phase 3 clinical

The trial known as MONALEESA-7 met its primary endpoint of progression-free survival (PFS), stated Novartis. Through the late-stage trial, the CDK4/6 inhibitor Kisqali in combination with oral hormonal

The NEPLEX (nephron on a chip with cellular and extracellular matrix complexity) consortium will aggregate crucial technologies to develop and build a novel drug discovery device called Nephron-on-a-Chip.

Spark Therapeutics will enroll up to five additional participants in the current Phase 1/2 clinical trial who will receive SPK-9001 manufactured using an enhanced process to test its

Zelboraf has been approved for the first line treatment of patients with Erdheim-Chester disease (ECD) and who are positive for BRAF V600 mutation. ECD is a rare and serious

With Splunk, Recursion has combined biological science with machine learning to generate and analyze data from tens of thousands of images of cell cultures and trillions of DNA

The 48-week data showed that Cyltezo is equivalent, with no clinically meaningful differences in efficacy, safety and immunogenicity to Humira in people with moderately-to-severely active rheumatoid arthritis (RA),